No Data
No Data
Theralase Technologies Inc.'s (CVE:TLT) Path To Profitability
Theralase(R) Expands Clinical Team
TORONTO, ON / ACCESSWIRE / May 2, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and devel
Theralase(R) Closes $CAN 750,000 Non-Brokered Private Placement
TORONTO, ON / ACCESSWIRE / April 24, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF)(FRA:TTX), a clinical stage pharmaceutical company dedicated to the resear
Theralase(R) Granted Canadian Cancer Vaccine Patent
TORONTO, ON / ACCESSWIRE / April 5, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and dev
Earnings Call Summary | THERALASE TECHNOLOGIES INC(TLTFF.US) Q4 2023 Earnings Conference
The following is a summary of the Theralase Technologies Inc. (TLTFF) Q4 2023 Earnings Call Transcript:Financial Performance:Theralase Technologies reported a 6% YoY decrease in sales to $1.07 million
Theralase(R) Release's 4Q2023 Interim Financial Statements
TORONTO, ON / ACCESSWIRE / March 27, 2024 / Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage pharmaceutical company dedicated to the research and de